Episode
Eli Lilly’s Vaccine Bet for the Future
- Published
- Jun 6, 2026
- Duration seconds
- 98
- Processing state
not_requested
Actions
POST https://stenobird.com/v1/public/podcasts/business-finance-news-today-2-min-news-the-daily-news-now-7726192/episodes/eli-lilly-s-vaccine-bet-for-the-future/transcription-requests
Idempotently request low-priority transcript generation for this episode.GET https://stenobird.com/podcast/business-finance-news-today-2-min-news-the-daily-news-now-7726192/eli-lilly-s-vaccine-bet-for-the-future.md
Read the agent-friendly Markdown representation of this episode resource.
Summary
Eli Lilly just splashed three point eight billion on vaccine companies, quietly shifting gears from its cash-gushing GLP-1 drugs like Mounjaro and Zepbound. While investors fixate on those blockbuster earners, this move is a strategic long-term play to diversify into infectious disease territory — a smart hedge against patent expiration and revenue slowdowns. It’s not flashy now, but it’s a calculated step toward building a more resilient, future-proof pharmaceutical powerhouse. Support the show: Get a discount at https://solipillow.com/discount/dnn. Advertise on DNN: [email protected] This is an automated, high-level news summary based on public reporting. Report issues to [email protected]. View sources & latest updates: https://sources.thednn.ai/374eb1ddc06eaab0